AL-15469A for the Treatment of Bacterial Conjunctivitis

The purpose of the study is to determine whether AL-15469A is safe and effective in the treatment of bacterial conjunctivitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Bacterial Conjunctivitis Bacterial Infections Bacterial Infections and Mycoses Conjunctival Diseases Conjunctivitis Conjunctivitis, Bacterial Eye Diseases Eye Infections Eye Infections, Bacterial Infections

Age range

1 month and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

US

Fort Worth, Texas, 76134, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Signs & Symptoms of conjunctivitis

Exclusion criteria

Under 1 mo. age

Treatment and study plan

quinolone

Drug

Primary outcomes

Clinical cure and microbiological success

Secondary outcomes

Individual signs and symptoms of bacterial conjunctivitis at each visit

Sponsors and collaborators

Lead sponsor

Alcon Research

Industry

Registry information

Important dates

Study start: 2005
Primary completion: 2007
First posted: May 31, 2006
Registry last updated: Sep 29, 2009

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed